AbbVie Reports the P-II (PICCOLO) Study Data of Elahere (Mirvetuximab Soravtansine) for Treating Ovarian Cancer
Shots:
- The P-II (PICCOLO) study assesses Elahere's safety & efficacy alone to treat FRα high Pt-sensitive ovarian cancer patients administered with at least 2 previous lines of Pt-based treatment or have a documented Pt allergy
- The study reached the 1EPs, showing a 51.9% ORR & 2EP, depicting 8.25mos. mDoR with a safety profile aligning with the prior studies without any new safety signals reported. Full results will be featured at upcoming conferences
- Elahere is an ADC consisting of a FRα-binding Ab, cleavable linker & the maytansinoid payload DM4 to destroy targeted cancer cells. It is further being evaluated in the P-III (GLORIOSA) study with bevacizumab vs bevacizumab monotx. in maintenance post 2L Pt-doublet therapy for PSOC
Ref: AbbVie | Image: AbbVie
Related News:- ImmunoGen Collaborates with Takeda to Develop and Commercialize Elahere to Treat Platinum-Resistant Ovarian Cancer in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
